Investigational drug · Phase 3
TDI01
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for GVHD, Chronic, Idiopathic Pulmonary Fibrosis (IPF).
Phase 3Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "TDI01"
First trial start
2024
Feb 6, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TDI01", any sponsor or status.
Conditions studied
As listed on its trial records.
- GVHD, Chronic
- Idiopathic Pulmonary Fibrosis (IPF)
Approved drugs for the same conditions: Idiopathic pulmonary fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "TDI01" as an intervention, largest first.
- A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingRecruiting
Beijing Tide Pharmaceutical Co., LtdIndustry
NCT07464912 · 508 participants (planned) · Start Dec 24, 2025 · Primary completion Jul 30, 2029
Drug: TDI01 · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Beijing, China
- A Clinical Trial on the Treatment of Idiopathic Pulmonary FibrosisPivotal-lookingStatus unknown
Beijing Tide Pharmaceutical Co., LtdIndustry
NCT06102083 · 120 participants (planned) · Start Nov 2, 2023 · Primary completion Aug 1, 2025
Drug: TDI01 suspension · For: Idiopathic Pulmonary Fibrosis
- TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))Active, not recruiting
Beijing Tide Pharmaceutical Co., LtdIndustry
NCT06169722 · 60 participants (planned) · Start Feb 6, 2024 · Primary completion Feb 2026
Drug: TDI01 suspension · For: GVHD, Chronic
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Differential functions of ROCK1 and ROCK2 in liver fibrosis and advances in targeted therapeutic strategies.
He T, Li Y, Chen Z, et al. · Front Pharmacol 2026
- Novel highly selective ROCK2 inhibitor (TDI01) for the treatment of chronic graft-versus-host disease: a multicenter, open-label phase Ib/II study.
Mo X, Zhang X, Guo R, et al. · Signal Transduct Target Ther 2026
- ROCK2 inhibitor targets vascular niche angiocrine signaling in liver fibrosis.
Sun P, Wang C, Li W · Trends Pharmacol Sci 2026
- Selective targeting of endothelial and perivascular angiocrine ROCK2 treats liver fibrosis.
Hu Y, Yang B, Xiao C, et al. · Cell 2026
- New molecules in the therapy of chronic graft-versus-host disease.
Steiner L, Klein SA, Kreil S · Curr Opin Hematol 2025
- Model-informed drug development of novel ROCK2 inhibitor TDI01: population pharmacokinetic study and simulation.
Ji X, Cui Y · Front Pharmacol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.